Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Salivary Gland Carcinoma: early-phase trial registry
1 of 6 indexed Recurrent Salivary Gland Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Recurrent Salivary Gland Carcinoma: 6 US clinical trials tracked, 1 recruiting.
Recurrent Salivary Gland Carcinoma is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition recurrent-salivary-gland-carcinoma
OPEN 1 | RECR 17% | LATE 1 | EARLY 5 | RANK #2866 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)
Recurrent Salivary Gland Carcinoma lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Salivary Gland Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Salivary Gland Carcinoma is recruiting below its size-band peers.
1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Salivary Gland Carcinoma research.
National Cancer Institute (NCI) accounts for 4 of 6 trials (66.7%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Salivary Gland Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Recurrent Salivary Gland Carcinoma research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NRG Oncology
NCT05408845
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
National Cancer Institute (NCI)
NCT00588770
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Mayo Clinic
NCT04895735
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
NCT05669664
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
National Cancer Institute (NCI)
NCT04576091
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
National Cancer Institute (NCI)
NCT00859937
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Salivary Gland Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Salivary Gland Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Salivary Gland Carcinoma page
6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Salivary Gland Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Salivary Gland Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Salivary Gland Carcinoma condition card totals 6 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.